SubscribeAll Posts Tagged With: "biotech"
This Bet Pays Off More Than 80% of the Time
You would have made 78% in one day…
Last month, a small biotech company – Synta Pharmaceuticals – suffered a huge drop in its share price. The company announced its lead drug, which treats skin cancer, failed in a pivotal Phase III trial. The stock dropped 78%…
Short sellers profit when stocks crash. And investors who "shorted" Synta’s – who bet against the drug’s approval – walked away with a big paycheck. But shareholders who stuck by Synta were probably shocked…
Synta’s management had done everything right. It ran a "placebo controlled" Phase II trial (that’s the middle hurdle) before it went to…
13Mar2009 | Stansberry and Associates | 0 comments | ContinuedUnprecedented Bright Spot in Market Downturn
Dear Reader,
It’s Thanksgiving and the markets are taking a well-deserved break. Frankly, they sure could use it. The recent volatility is unprecedented.
In the past 25 years there has been 50 days when the market moved up or down four percent. That seems like an average trading day now. It should. Half of those 50 moves occurred in the past two months. That’s right, 25 years of volatility was crammed into about two months of trading. So, yes, it’s going to be nice to have a long break (don’t worry about Friday, it’s a half day and volume is always…
27Nov2008 | Q1 Publishing | 0 comments | ContinuedHealthcare In a State of Flux
Long thought to be an industry that could be banked on for stability by defensive investors during periods of turmoil, the healthcare industry should now be carefully navigated.
Two sectors within the industry that are worth noting right now are healthcare providers and biotech. These two sectors have experienced drastically different fates so far in 2008, and the trend might be expected to continue. Year-to-date, the iShares Dow Jones Healthcare Provider Fund (IHF) has choked on a loss of 46.4%. This performance is worse than that of the S&P 500 which is down 39.2% so far this year. It is far…
27Oct2008 | Oxbury Research | Comments Off | ContinuedInvesting in Biotech: How to Profit from the 3 “Phases” of Clinical Trials
When it comes to investing in biotech, Marc Lichtenfeld is one of the smartest analysts in the field. He’s a pro at finding companies in this group that consistently outperform. But more importantly, I trust his opinion. Today, he’s showing us how a drug is brought to market, and the best way to profit from these announcements.
~ Alexander Green
Investing in biotech can be incredibly exciting and rewarding. After all, there’s nothing like getting in early on a company with a novel drug for cancer, diabetes or any other debilitating disease – watching the drug successfully navigate clinical trials and then…
2Sep2008 | Investment U | Comments Off | ContinuedThe Start to the Convergence Revolution
Nanotech/Biotech Convergence and Opportunities Accelerating
Not that long ago, the media were full of warnings that Big Pharma was running out of steam. Patents were expiring, and not enough new candidates were in the pipeline to keep them profitable.
We don’t have much interest in Big Pharma here. Big pharmaceutical companies simply don’t yield really dramatic returns. Usually, it takes a small-cap or startup to do that. Until recently, the odds were stacked against small companies, due to the costs of drug approval, which have become enormous.
Regulators may have the right motives, but bureaucracies are necessarily risk averse. Approving a drug that ends…
25Jul2008 | The Penny Sleuth | Comments Off | ContinuedSmall-Cap Vaccines
Small Wonders
The media have dubbed it “the new age of epidemics.†From SARS to cancer, diabetes to the flu, we live in a world of increasingly powerful germs and diseases.
Drug companies large and small have renewed their interest in one specific health care sector. It’s a true form of preventative medicine — a rapidly growing field that’s already decimated countless dangerous and deadly diseases.
Now biotechs and Big Pharma are in a race against time. Their mission is clear: Rid the world of the onslaught of superbugs and diseases that could cause the next great epidemic. And they’ll use second-generation technology…
24Jul2008 | Whiskey and Gunpowder | Comments Off | ContinuedSwitzerland’s Roche Makes $43.7 Billion Offer for U.S. Biotech Pioneer Genentech
Roche Holding Ltd. (OTC ADR: RHHBY) yesterday (Monday) announced a $43.7 billion offer for the 44% of Genentech Inc. (DNA) it doesn’t already own.
Switzerland-based Roche’s $89 per share cash offer is almost a 9% premium over San Francisco-based Genentech’s Friday closing price. Roche first acquired 60% of Genentech for $2.1 billion in a 1990 deal. Currently, Roche owns approximately 56% of outstanding Genentech shares.
Roche will finance the Genentech deal through a combination of new debt and $9.8 billion (10 billion Swiss francs) in cash.
“The transaction will create a unique opportunity to evolve Roche’s hub-and-spoke model into a structure that allows…
22Jul2008 | Money Morning | Comments Off | ContinuedBiotech Stocks: Opportunities abound for Osiris Therapeutics (OSIR:NASDAQ)
‘This Maryland-based biotechnology firm develops treatments for conditions as varied as Crohn’s disease, knee arthritis, tissue damage, life-threatening Graft-versus-host disease and acute radiation syndrome.’ – Laura Cadden
Osiris Therapeutics, Inc. creates therapeutic drugs from human mesenchymal stem cells (MSCs) retrieved from bone marrow donated by healthy adult volunteers.
Bone regeneration = big bucks
Earlier this month, Osiris announced the sale of its Osteocel unit to NuVasive for $85 million.
Osteocel promotes bone regeneration and is used in spinal fusion and other orthopedic procedures.
This deal provides Osiris with the money and ability to focus on the next generation of revolutionary products… products like Chondrogen, which works…
27May2008 | Laura Cadden | 1 comment | ContinuedProfit Opportunity: A diamond in a mud pit
This is a very scary period of time for investors. Just when they think they have the market figured out, it turns out to be a head fake and the market changes track.
If not careful, this market could become more than scary. It could be come downright dangerous. For many investors, it already has. The losses are piling up.
Across the nation, investors are running for cover. Nearly all economic barometers show a recession on the horizon. It is time to head to your storm shelters. When the markets are destined for a major slowdown, you need to take action.
Unfortunately, the…
4Apr2008 | Guest Contributor | Comments Off | Continued
Loading ...
